BMRN Q4 2018 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$353M-1.4% YoY

Gross Profit

$278M78.8% margin

Operating Income

-$38M-10.8% margin

Net Income

-$4M-1.0% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-9.8%

Cash Flow

Operating Cash Flow

$49M

Free Cash Flow

$7M

Stock-Based Comp.

$37M

Balance Sheet

Total Assets

$4.4B

Total Liabilities

$1.5B

Stockholders' Equity

$3.0B

Cash & Equivalents

$494M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$353M	$358M	-1.4%
Gross Profit	$278M	$282M	-1.5%
Operating Income	-$38M	$58M	-165.7%
Net Income	-$4M	-$51M	+92.9%

Revenue Segments

Product Four

$114M34%

Product Three

$112M33%

Product Two

$77M23%

Product Six

$12M4%

Product Seven

$8M2%

Product Five

$7M2%

Royalty And Other

$6M2%

Geographic Segments

UNITED STATES

$169M48%

Europe

$112M32%

Rest Of World

$39M11%

Latin America

$33M9%